Recent Updates
Recently added Catalysts

Tovecimig

Phase 2/3

Colorectal Cancer | Biologics | Oncology |Compass Therapeutics, Inc.|Trials Updated: Nov 20, 2026

Tovecimig development status

Highest phase Phase 2/3 (NCT05506943)
Phase scored for CMPXPhase 2
Registered trials 5 across 3 sponsors since Aug 2022

Tovecimig target and mechanism

ModalityBiologics

Also known as CTX-009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials4
Total Enrollment296

FDA Designations

No designations recorded

Tovecimig clinical trials

Tovecimig · 4 trials · 9 indications

Phase 2/3 1Phase 2 2Phase 1/2 1
NCT05506943A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)Biliary Tract Cancer
ACTIVE NOT_RECRUITING168 Analytics
PHASE2/PHASE3ACTIVE NOT_RECRUITING
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract CancerUnlock trial analytics

Study Endpoints

Primary Endpoints

Best Overall Response
From randomization to treatment discontinuation for any reason, average 6 months

Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions.

Overall Response Rate (ORR)
Start of treatment to completion of treatment (estimated time up to 12 months)

Defined as the proportion of patients who have a partial response (PR) or complete response (CR) per RECIST 1.1. CR is defined as disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Overall Response Rate
From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)

Percentage of patients whose best overall response is assessed as complete response (CR) or partial response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions.

Phase IB Arm 1: Toxicity as measured by number of participants with adverse events
Start of treatment through 60 days after treatment (estimated to be 14 months)

Adverse events will be graded according to CTCAE v6.0

Phase IB Arm 1: Recommended Phase 2 Dose (RP2D)
Start of treatment through completion of cycle 1 (each cycle is 28 days)

RP2D will be determined from the phase IB portion of Arm 1 by assessing tolerability. Tolerability is defined as ≤1 among patients experiencing excessive dose limiting toxicities (DLTs). The dose level in phase IB determined to be tolerable is the RP2D.

Phase IB Arm 2: Toxicity as measured by number of participants with adverse events
Start of treatment through 60 days after treatment (estimated to be 14 months)

Adverse events will be graded according to CTCAE v6.0

Phase II Arm 1: Overall survival rate at 12 months (OS12)
12 months

Overall survival is defined from time of treatment start to time of death due to any cause or latest follow-up, whichever is earlier, with an inference focus on 12-month overall survival.

Phase II Arm 2: Overall survival rate at 12 months (OS12)
12 months

Overall survival is defined from time of treatment start to time of death due to any cause or latest follow-up, whichever is earlier, with an inference focus on 12-month overall survival.

Secondary Endpoints

Progression Free Survival
From randomization to first documented objective PD or death if PD does not occur, average 6 months
Duration of Response
From first confirmed CR or PR to confirmed PD, average 6 months
Overall Survival
From randomization to death from any cause, average 12 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CTX-009 plus PaclitaxelEXPERIMENTAL -
PaclitaxelACTIVE_COMPARATORPatients randomized to receive paclitaxel only have the option to crossover to the CTX-009 plus paclitaxel arm after documented disease progression per RECIST v1.1.
Tovecimig and Irinotecan + Leucovorin + 5-Fluorouracil (FOLFIRI regimen)EXPERIMENTALTreatment will be administered in 28-day cycles. On Day 1 and 15 of each cycle, patients will receive Tovecimig followed by the FOLFIRI regimen.
CTX-009 TreatmentEXPERIMENTAL -
Phase IB Arm 1: CTX-009 monotherapyEXPERIMENTALCTX-009 will be given intravenously at the assigned dose level on an outpatient basis every 2 weeks of a 28-day cycle.
Phase IB Arm 2: CTX-009 and CTX-471 combination therapyEXPERIMENTALCTX-009 will be given intravenously at the dose determined to be the recommended phase II dose (RP2D) in Arm 1 every 2 weeks, and CTX-471 will be given intravenously at a dose of 0.3 mg/kg every 2 weeks (day 1 and day 15). On days when both drugs are given, CTX-009 will be given first, followed by a 30-minute observation period, followed by CTX-471. Cycles will be 28 days.
Phase II Expansion Arm 1: CTX-009 monotherapyEXPERIMENTALCTX-009 will be given intravenously at the recommended phase 2 dose (RP2D) determined from Phase IB on an outpatient basis every 2 weeks of a 28-day cycle.
Phase II Expansion Arm 2: CTX-009 and CTX-471 combination therapyEXPERIMENTALCTX-009 will be given intravenously at the dose determined to be the recommended phase II dose (RP2D) every 2 weeks (day 1 and day 15). CTX-471 will be given intravenously at a dose of 0.3 mg/kg every 2 weeks (day 1 and day 15). On days when both drugs are given, CTX-009 will be given first, followed by a 30-minute observation period, followed by CTX-471. Cycles will be 28 days.

Interventions

NameTypeDescription
CTX-009DRUGIV infusion on day 1 and 14 of every 28 day cycle
PaclitaxelDRUGIV infusion on day 1, 8, and 15 of every 28 day cycle
TovecimigBIOLOGICALTovecimig is provided in 10 mg/kg dose intravenously over the course of 60 minutes on Day 1 and Day 15 of a 28-day cycle.
IrinotecanDRUGStandard of care irinotecan will be given at a dose of 180 mg/m\^2 intravenously on Day 1 and Day 15 of each 28-day cycle as part of the FOLFIRI treatment regimen.
LeucovorinDRUGStandard of care leucovorin will be given at a dose of 400 mg/m\^2 intravenously on Day 1 and Day 15 of each 28-day cycle as part of the FOLFIRI treatment regimen.
5-Fluorouracil (5-FU)DRUGStandard of care 5-FU will be given at a dose of 2400 mg/m\^2 in continuous infusion over 46 hours on Days 1-2 and Days 15-16 of each 28-day cycle as part of the FOLFIRI treatment regimen.
CTX-471DRUGCTX-471 will be given intravenously over the course of 30 minutes (-5/+10) on an outpatient basis every 2 weeks of a 28-day cycle.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites34

INCLUSION CRITERIA 1. 18 years of age or older 2. Histologically or cytologically confirmed unresectable advanced, metastatic, or recurrent biliary tract cancers (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma) 3. Patients mus...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Colorectal Cancer 355 trials

Top 20 of 78 competitors

Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWNov 20, 2026NCT07662031lastUpdatePostDate: changed
MEDIUMNov 10, 2026NCT07662031primaryCompletionDate: changed
LOWNov 10, 2026NCT07392957Status: NOT_YET_RECRUITING → RECRUITING
LOWNov 10, 2026NCT05506943lastUpdatePostDate: changed
MEDIUMNov 10, 2026NCT07662031primaryCompletionDate: changed
LOWNov 10, 2026NCT07392957Status: NOT_YET_RECRUITING → RECRUITING
LOWNov 10, 2026NCT05506943lastUpdatePostDate: changed
MEDIUMNov 10, 2026NCT07662031primaryCompletionDate: changed
LOWNov 10, 2026NCT07392957Status: NOT_YET_RECRUITING → RECRUITING
LOWNov 6, 2026NCT05506943lastUpdatePostDate: changed
LOWNov 6, 2026NCT05506943lastUpdatePostDate: changed
MEDIUMOct 26, 2026NCT05513742TRIAL_REMOVED: changed
MEDIUMOct 26, 2026NCT05513742TRIAL_REMOVED: changed
MEDIUMOct 26, 2026NCT05513742TRIAL_REMOVED: changed
MEDIUMOct 26, 2026NCT05513742TRIAL_REMOVED: changed
MEDIUMSep 2, 2026NCT05506943primaryCompletionDate: changed
MEDIUMSep 2, 2026NCT05506943primaryCompletionDate: changed
MEDIUMSep 2, 2026NCT05506943primaryCompletionDate: changed

Frequently asked questions about Tovecimig

What is Tovecimig used for?

Tovecimig is an investigational monoclonal antibody being studied for the treatment of colorectal cancer, specifically metastatic colorectal cancer. It is being evaluated in the second-line setting, meaning for patients whose disease has progressed after earlier therapy. It is not approved for any use and remains in clinical development.

Who is developing Tovecimig?

Tovecimig is being developed by Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company that trades under the ticker symbol CMPX. Compass Therapeutics is the sponsor of the clinical program evaluating tovecimig in metastatic colorectal cancer.

What phase is Tovecimig in?

Tovecimig is in Phase 2 clinical development. The ongoing study is a Phase 2 trial, and the drug is investigational, meaning it has not been approved by the FDA or any other regulatory authority for commercial use.

What clinical trial is Tovecimig in?

Tovecimig is being studied in the trial NCT07662031, titled Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer. The Phase 2 study is not yet recruiting, is expected to enroll 25 participants, and is being conducted in the United States in adults aged 18 years and older.

How is the Tovecimig trial designed?

The Phase 2 trial NCT07662031 evaluates tovecimig in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer in the second-line setting. It is an uncontrolled, open-label study without randomization or blinding, and it plans to enroll 25 participants across sites in the United States.